BMB Reports

생화학분자생물학회 (Korean Society for Biochemistry and Molecular Biology)
권호 표지
DOI QR코드

DOI QR Code

Therapeutic application of extracellular vesicles for various kidney diseases: a brief review

  • Lee, Sul A (Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine) ;
  • Yoo, Tae Hyun (Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University)
  • 투고 : 2021.09.13
  • 심사 : 2021.12.10
  • 발행 : 2022.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Extracellular vesicles (EVs) released from different types of kidney cells under physiologic conditions contribute to homeostasis maintenance, immune-modulation, and cell-to-cell communications. EVs can also negatively affect the progression of renal diseases through their pro-inflammatory, pro-fibrotic, and tumorigenic potential. Inhibiting EVs by blocking their production, release, and uptake has been suggested as a potential therapeutic mechanism based on the significant implication of exosomes in various renal diseases. On the other hand, stem cell-derived EVs can ameliorate tissue injury and mediate tissue repair by ameliorating apoptosis, inflammation, and fibrosis while promoting angiogenesis and tubular cell proliferation. Recent advancement in biomedical engineering technique has made it feasible to modulate the composition of exosomes with diverse biologic functions, making EV one of the most popular drug delivery tools. The objective of this review was to provide updates of recent clinical and experimental findings on the therapeutic potential of EVs in renal diseases and discuss the clinical applicability of EVs in various renal diseases.

키워드

과제정보

The authors thank Medical Illustration & Design, part of the Medical Research Support Services of Yonsei University College of Medicine, for all artistic support related to this work.

참고문헌

  1. Karpman D, Stahl AL and Arvidsson I (2017) Extracellular vesicles in renal disease. Nat Rev Nephrol 13, 545-562 https://doi.org/10.1038/nrneph.2017.98
  2. Lipschutz JH (2019) The role of the exocyst in renal ciliogenesis, cystogenesis, tubulogenesis, and development. Kidney Res Clin Pract 38, 260-266 https://doi.org/10.23876/j.krcp.19.050
  3. Lee SA, Choi C and Yoo TH (2021) Extracellular vesicles in kidneys and their clinical potential in renal diseases. Kidney Res Clin Pract 40, 194-207 https://doi.org/10.23876/j.krcp.20.209
  4. Linxweiler J and Junker K (2020) Extracellular vesicles in urological malignancies: an update. Nat Rev Urol 17, 11-27 https://doi.org/10.1038/s41585-019-0261-8
  5. Jing H, Tang S, Lin S, Liao M, Chen H and Zhou J (2019) The role of extracellular vesicles in renal fibrosis. Cell Death Dis 10, 367 https://doi.org/10.1038/s41419-019-1605-2
  6. Behrens F, Holle J, Kuebler WM and Simmons S (2020) Extracellular vesicles as regulators of kidney function and disease. Intensive Care Med Exp 8, 22 https://doi.org/10.1186/s40635-020-00306-2
  7. Xu M, Yang Q, Sun X and Wang Y (2020) Recent advancements in the loading and modification of therapeutic exosomes. Front Bioeng Biotechnol 8, 586130 https://doi.org/10.3389/fbioe.2020.586130
  8. Bochon B, Kozubska M, Surygala G et al (2019) Mesenchymal stem cells-potential applications in kidney diseases. Int J Mol Sci 20, 2462 https://doi.org/10.3390/ijms20102462
  9. Chen W, Yan Y, Song C, Ding Y and Du T (2017) Microvesicles derived from human Wharton's Jelly mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal fibrosis by releasing from G2/M cell cycle arrest. Biochem J 474, 4207-4218 https://doi.org/10.1042/BCJ20170682
  10. Zhang G, Zou X, Miao S et al (2014) The anti-oxidative role of micro-vesicles derived from human Wharton-Jelly mesenchymal stromal cells through NOX2/gp91(phox) suppression in alleviating renal ischemia-reperfusion injury in rats. PLoS One 9, e92129 https://doi.org/10.1371/journal.pone.0092129
  11. Li X, Liao J, Su X et al (2020) Human urine-derived stem cells protect against renal ischemia/reperfusion injury in a rat model via exosomal miR-146a-5p which targets IRAK1. Theranostics 10, 9561-9578 https://doi.org/10.7150/thno.42153
  12. Zhu G, Pei L, Lin F et al (2019) Exosomes from humanbone-marrow-derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR-199a-3p. J Cell Physiol 234, 23736-23749 https://doi.org/10.1002/jcp.28941
  13. Pan T, Jia P, Chen N et al (2019) Delayed remote ischemic preconditioning confers renoprotection against septic acute kidney injury via exosomal miR-21. Theranostics 9, 405-423 https://doi.org/10.7150/thno.29832
  14. Grange C, Papadimitriou E, Dimuccio V et al (2020) Urinary extracellular vesicles carrying Klotho improve the recovery of renal function in an acute tubular injury model. Mol Ther 28, 490-502 https://doi.org/10.1016/j.ymthe.2019.11.013
  15. Christov M, Neyra JA, Gupta S and Leaf DE (2019) Fibroblast growth factor 23 and Klotho in AKI. Semin Nephrol 39, 57-75 https://doi.org/10.1016/j.semnephrol.2018.10.005
  16. Dominguez JM 2nd, Dominguez JH, Xie D and Kelly KJ (2018) Human extracellular microvesicles from renal tubules reverse kidney ischemia-reperfusion injury in rats. PLoS One 13, e0202550 https://doi.org/10.1371/journal.pone.0202550
  17. Brigstock DR (2021) Extracellular vesicles in organ fibrosis: mechanisms, therapies, and diagnostics. Cells 10, 1596 https://doi.org/10.3390/cells10071596
  18. Ebrahim N, Ahmed IA, Hussien NI et al (2018) Mesenchymal stem cell-derived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway. Cells 7, 226 https://doi.org/10.3390/cells7120226
  19. Nagaishi K, Mizue Y, Chikenji T et al (2016) Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci Rep 6, 34842 https://doi.org/10.1038/srep34842
  20. Lindoso RS, Lopes JA, Binato R et al (2020) Adipose mesenchymal cells-derived EVs alleviate DOCA-salt-induced hypertension by promoting cardio-renal protection. Mol Ther Methods Clin Dev 16, 63-77 https://doi.org/10.1016/j.omtm.2019.11.002
  21. Cambier L, Giani JF, Liu W et al (2018) Angiotensin II-induced end-organ damage in mice is attenuated by human exosomes and by an exosomal Y RNA fragment. Hypertension 72, 370-380 https://doi.org/10.1161/HYPERTENSIONAHA.118.11239
  22. Cantaluppi V, Medica D, Mannari C et al (2015) Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis. Nephrol Dial Transplant 30, 410-422 https://doi.org/10.1093/ndt/gfu364
  23. Eirin A, Zhu XY, Puranik AS et al (2017) Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation. Kidney Int 92, 114-124 https://doi.org/10.1016/j.kint.2016.12.023
  24. Song T, Eirin A, Zhu X et al (2020) Mesenchymal stem cell-derived extracellular vesicles induce regulatory t cells to ameliorate chronic kidney injury. Hypertension 75, 1223-1232 https://doi.org/10.1161/hypertensionaha.119.14546
  25. Quaglia M, Dellepiane S, Guglielmetti G, Merlotti G, Castellano G and Cantaluppi V (2020) Extracellular vesicles as mediators of cellular crosstalk between immune system and kidney graft. Front Immunol 11, 74 https://doi.org/10.3389/fimmu.2020.00074
  26. Yu X, Huang C, Song B et al (2013) CD4+CD25+ regulatory T cells-derived exosomes prolonged kidney allograft survival in a rat model. Cell Immunol 285, 62-68 https://doi.org/10.1016/j.cellimm.2013.06.010
  27. Pang XL, Wang ZG, Liu L et al (2019) Immature dendritic cells derived exosomes promotes immune tolerance by regulating T cell differentiation in renal transplantation. Aging (Albany NY) 11, 8911-8924 https://doi.org/10.18632/aging.102346
  28. Wu X, Yan T, Wang Z et al (2018) Micro-vesicles derived from human Wharton's Jelly mesenchymal stromal cells mitigate renal ischemia-reperfusion injury in rats after cardiac death renal transplantation. J Cell Biochem 119, 1879-1888 https://doi.org/10.1002/jcb.26348
  29. Nomura S, Takahashi N, Inami N et al (2004) Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 174, 329-335 https://doi.org/10.1016/j.atherosclerosis.2004.01.027
  30. Nomura S, Inami N, Shouzu A et al (2009) The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 20, 16-22 https://doi.org/10.1080/09537100802409921
  31. Dasgupta SK, Le A, Chavakis T, Rumbaut RE and Thiagarajan P (2012) Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. Circulation 125, 1664-1672 https://doi.org/10.1161/CIRCULATIONAHA.111.068833
  32. Mossberg M, Stahl AL, Kahn R et al (2017) C1-inhibitor decreases the release of vasculitis-like chemotactic endothelial microvesicles. J Am Soc Nephrol 28, 2472-2481 https://doi.org/10.1681/ASN.2016060637
  33. Liu X, Miao J, Wang C et al (2020) Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis. Kidney Int 97, 1181-1195 https://doi.org/10.1016/j.kint.2019.11.026
  34. Borges FT, Reis LA and Schor N (2013) Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Braz J Med Biol Res 46, 824-830 https://doi.org/10.1590/1414-431X20132964
  35. Jiang XC and Gao JQ (2017) Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm 521, 167-175 https://doi.org/10.1016/j.ijpharm.2017.02.038
  36. Kato M (2018) Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease. Kidney Res Clin Pract 37, 197-209 https://doi.org/10.23876/j.krcp.2018.37.3.197
  37. Tang TT, Lv LL, Wang B et al (2019) Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis. Theranostics 9, 4740-4755 https://doi.org/10.7150/thno.33520
  38. Yim N, Ryu SW, Choi K et al (2016) Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun 7, 12277 https://doi.org/10.1038/ncomms12277
  39. Choi H, Kim Y, Mirzaaghasi A et al (2020) Exosome-based delivery of super-repressor IκBα relieves sepsis-associated organ damage and mortality. Sci Adv 6, eaaz6980 https://doi.org/10.1126/sciadv.aaz6980
  40. Kim S, Lee SA, Yoon H et al (2021) Exosome-based delivery of super-repressor IκBα ameliorates kidney ischemia-reperfusion injury. Kidney Int 100, 570-584 https://doi.org/10.1016/j.kint.2021.04.039
  41. Wang B, Yao K, Huuskes BM et al (2016) Mesenchymal stem cells deliver exogenous microRNA-let7c via exosomes to attenuate renal fibrosis. Mol Ther 24, 1290-1301 https://doi.org/10.1038/mt.2016.90
  42. Zhang A, Wang H, Wang B, Yuan Y, Klein JD and Wang XH (2019) Exogenous miR-26a suppresses muscle wasting and renal fibrosis in obstructive kidney disease. FASEB J 33, 13590-13601 https://doi.org/10.1096/fj.201900884R
  43. Wang H, Wang B, Zhang A et al (2019) Exosome-mediated miR-29 transfer reduces muscle atrophy and kidney fibrosis in mice. Mol Ther 27, 571-583 https://doi.org/10.1016/j.ymthe.2019.01.008
  44. Gu D, Zou X, Ju G, Zhang G, Bao E and Zhu Y (2016) Mesenchymal stromal cells derived extracellular vesicles ameliorate acute renal ischemia reperfusion injury by inhibition of mitochondrial fission through miR-30. Stem Cells Int 2016, 2093940
  45. Ju GQ, Cheng J, Zhong L et al (2015) Microvesicles derived from human umbilical cord mesenchymal stem cells facilitate tubular epithelial cell dedifferentiation and growth via hepatocyte growth factor induction. PLoS One 10, e0121534 https://doi.org/10.1371/journal.pone.0121534
  46. Du T, Zhou J, Chen WX et al (2020) Microvesicles derived from human umbilical cord mesenchymal stem cells ameliorate renal ischemia-reperfusion injury via delivery of miR-21. Cell Cycle 19, 1285-1297 https://doi.org/10.1080/15384101.2020.1748940
  47. Collino F, Lopes JA, Correa S et al (2019) Adipose-derived mesenchymal stromal cells under hypoxia: changes in extracellular vesicles secretion and improvement of renal recovery after ischemic injury. Cell Physiol Biochem 52, 1463-1483
  48. Xiang E, Han B, Zhang Q et al (2020) Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther 11, 336 https://doi.org/10.1186/s13287-020-01852-y
  49. Grange C, Tritta S, Tapparo M et al (2019) Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci Rep 9, 4468 https://doi.org/10.1038/s41598-019-41100-9
  50. Nassar W, El-Ansary M, Sabry D et al (2016) Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res 20, 21 https://doi.org/10.1186/s40824-016-0068-0
  51. Jin J, Qian F, Zheng D, He W, Gong J and He Q (2021) Mesenchymal stem cells attenuate renal fibrosis via exosomes-mediated delivery of microRNA Let-7i-5p antagomir. Int J Nanomedicine 16, 3565-3578 https://doi.org/10.2147/IJN.S299969
  52. Du T, Ju G, Zhou J et al (2021) Microvesicles derived from human umbilical cord mesenchyme promote M2 macrophage polarization and ameliorate renal fibrosis following partial nephrectomy via hepatocyte growth factor. Hum Cell 34, 1103-1113 https://doi.org/10.1007/s13577-021-00525-z
  53. Chen L, Wang Y, Li S et al (2020) Exosomes derived from GDNF-modified human adipose mesenchymal stem cells ameliorate peritubular capillary loss in tubulointerstitial fibrosis by activating the SIRT1/eNOS signaling pathway. Theranostics 10, 9425-9442 https://doi.org/10.7150/thno.43315